WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555788

CAS#: 1445379-92-9

Description: ALS-8112, also known as ALS-008112, is a potent and selective respiratory syncytial virus (RSV) polymerase inhibitor. ALS-8112 is the parent nucleoside of lumicitabine, which has been evaluated in phase I and II clinical trials to treat pediatric and adult respiratory syncytial virus infection. The antiviral activity of ALS-8112 is mediated by its 5'-triphosphate metabolite (ALS-8112-TP, or 2'F-4'ClCH2-cytidine triphosphate) inhibiting the RNA polymerase activity of the RSV L-P protein complex through RNA chain termination.

Chemical Structure

CAS# 1445379-92-9

Theoretical Analysis

MedKoo Cat#: 555788
Name: ALS-8112
CAS#: 1445379-92-9
Chemical Formula: C10H13ClFN3O4
Exact Mass: 293.0579
Molecular Weight: 293.6794
Elemental Analysis: C, 40.90; H, 4.46; Cl, 12.07; F, 6.47; N, 14.31; O, 21.79

Price and Availability

Size Price Availability Quantity
5.0mg USD 650.0 2 Weeks
10.0mg USD 1150.0 2 Weeks
Bulk inquiry

Synonym: ALS-8112; ALS 8112; ALS8112; ALS-008112; ALS 008112; ALS008112;

IUPAC/Chemical Name: 4-amino-1-((2R,3R,4R,5R)-5-(chloromethyl)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one


InChi Code: InChI=1S/C10H13ClFN3O4/c11-3-10(4-16)7(17)6(12)8(19-10)15-2-1-5(13)14-9(15)18/h1-2,6-8,16-17H,3-4H2,(H2,13,14,18)/t6-,7+,8-,10-/m1/s1

SMILES Code: OC[C@]1(CCl)[C@@H](O)[C@@H](F)[C@H](N2C(N=C(N)C=C2)=O)O1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 293.6794 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Kasthuri M, Li C, Verma K, Russell OO, Dickson L, McCormick L, Bassit L, Amblard F, Schinazi RF. Synthesis of 4'-Substituted-2'-Deoxy-2'-α-Fluoro Nucleoside Analogs as Potential Antiviral Agents. Molecules. 2020 Mar 11;25(6):1258. doi: 10.3390/molecules25061258. PMID: 32168734; PMCID: PMC7143966.

2: Lo MK, Amblard F, Flint M, Chatterjee P, Kasthuri M, Li C, Russell O, Verma K, Bassit L, Schinazi RF, Nichol ST, Spiropoulou CF. Potent in vitro activity of β-D-4'-chloromethyl-2'-deoxy-2'-fluorocytidine against Nipah virus. Antiviral Res. 2020 Mar;175:104712. doi: 10.1016/j.antiviral.2020.104712. Epub 2020 Jan 11. PMID: 31935422; PMCID: PMC7054849.

3: Patel K, Kirkpatrick CM, Nieforth KA, Chanda S, Zhang Q, McClure M, Fry J, Symons JA, Blatt LM, Beigelman L, DeVincenzo JP, Huntjens DR, Smith PF. Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans. J Antimicrob Chemother. 2019 Feb 1;74(2):442-452. doi: 10.1093/jac/dky415. PMID: 30376079.

4: Brookes DW, Coates M, Allen H, Daly L, Constant S, Huang S, Hows M, Davis A, Cass L, Ayrton J, Knowles I, Strong P, Rapeport G, Ito K. Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium. Br J Pharmacol. 2018 Jun;175(12):2520-2534. doi: 10.1111/bph.14221. Epub 2018 May 2. PMID: 29579332; PMCID: PMC5980447.

5: Jordan PC, Stevens SK, Tam Y, Pemberton RP, Chaudhuri S, Stoycheva AD, Dyatkina N, Wang G, Symons JA, Deval J, Beigelman L. Activation Pathway of a Nucleoside Analog Inhibiting Respiratory Syncytial Virus Polymerase. ACS Chem Biol. 2017 Jan 20;12(1):83-91. doi: 10.1021/acschembio.6b00788. Epub 2016 Nov 22. PMID: 28103684.

6: Deval J, Fung A, Stevens SK, Jordan PC, Gromova T, Taylor JS, Hong J, Meng J, Wang G, Dyatkina N, Prhavc M, Symons JA, Beigelman L. Biochemical Effect of Resistance Mutations against Synergistic Inhibitors of RSV RNA Polymerase. PLoS One. 2016 May 10;11(5):e0154097. doi: 10.1371/journal.pone.0154097. PMID: 27163448; PMCID: PMC4862670.

7: Deval J, Hong J, Wang G, Taylor J, Smith LK, Fung A, Stevens SK, Liu H, Jin Z, Dyatkina N, Prhavc M, Stoycheva AD, Serebryany V, Liu J, Smith DB, Tam Y, Zhang Q, Moore ML, Fearns R, Chanda SM, Blatt LM, Symons JA, Beigelman L. Molecular Basis for the Selective Inhibition of Respiratory Syncytial Virus RNA Polymerase by 2'-Fluoro-4'-Chloromethyl-Cytidine Triphosphate. PLoS Pathog. 2015 Jun 22;11(6):e1004995. doi: 10.1371/journal.ppat.1004995. PMID: 26098424; PMCID: PMC4476725.